Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...
Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...
Johnson & Johnson price target raised to $166 from $159 at Barclays
Barclays raised the firm’s price target on Johnson & Johnson to $166 from $159 and keeps an Equal Weight rating on the shares. The company ...